[
  {
    "ts": "2026-01-05T08:30:00+00:00",
    "headline": "Sterility Testing Market to Reach US$ 3,913.35 Million by 2035 Amid Rising Global Clinical Trial Activity Says Astute Analytica",
    "summary": "Robust expansion currently defines the landscape as major players like Eli Lilly and Merck aggressively fund new manufacturing facilities. Concurrently, the industry embraces rapid technological advancements in automated membrane filtration to streamline critical quality assurance processes.Chicago, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The global sterility testing market was valued at US$ 1,344.31 million in 2025 and is expected to reach US$ 3,913.35 million by 2035, growing at a CAGR of 11.36% dur",
    "url": "https://finance.yahoo.com/news/sterility-testing-market-reach-us-083000138.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "98cccf96-7333-3e8c-b8bd-208a47d161a3",
      "content": {
        "id": "98cccf96-7333-3e8c-b8bd-208a47d161a3",
        "contentType": "STORY",
        "title": "Sterility Testing Market to Reach US$ 3,913.35 Million by 2035 Amid Rising Global Clinical Trial Activity Says Astute Analytica",
        "description": "",
        "summary": "Robust expansion currently defines the landscape as major players like Eli Lilly and Merck aggressively fund new manufacturing facilities. Concurrently, the industry embraces rapid technological advancements in automated membrane filtration to streamline critical quality assurance processes.Chicago, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The global sterility testing market was valued at US$ 1,344.31 million in 2025 and is expected to reach US$ 3,913.35 million by 2035, growing at a CAGR of 11.36% dur",
        "pubDate": "2026-01-05T08:30:00Z",
        "displayTime": "2026-01-05T08:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471",
          "originalWidth": 300,
          "originalHeight": 300,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JHwPm5XOBkH6S4g8iMmLiw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 300,
              "height": 300,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SbelUm4u7tLxgdG5STxR1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sterility-testing-market-reach-us-083000138.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sterility-testing-market-reach-us-083000138.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T12:36:16+00:00",
    "headline": "Novo Nordisk launches Wegovy pill to US self-pay patients",
    "summary": "<body><p>STORY: Novo Nordisk is due to launch its once-daily Wegovy weightloss pill in the U.S. from Monday (January 5).</p><p>The Danish drugmaker said it will offer 1.5 and 4 milligram pills at $149 per month to self-paying patients.</p><p>The U.S. Food and Drug Administration approved the pill last month.</p><p>It was a major boost for Novo as it tries to regain lost ground from U.S. rival Eli Lilly.</p><p>It offers a more flexible regime and an alternative for those who don't like needles used in injectable medication.</p><p>The launch could be a positive step for a company which saw profit warnings and sliding shares through last year.</p><p>The semaglutide pills contain the same active ingredient as injectable Wegovy and Ozempic.</p><p>The weight-loss pill version will also be a test case for the fast-growing cash-paying consumer market.</p><p>A key part of making it a success will be attracting cash-paying consumers who can't get insurance coverage.</p><p>That's a big shift from a business model where drug pricing is managed through health insurance plans, which has dominated for decades.</p><p>Novo also said the pill will be sold in 9 mg and a higher long-term dose of 25 mg, which will cost nearly $300 per month.</p></body>",
    "url": "https://finance.yahoo.com/video/novo-nordisk-launches-wegovy-pill-123616915.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "fc0bbc56-973d-333a-b9cf-810e9b1285ca",
      "content": {
        "id": "fc0bbc56-973d-333a-b9cf-810e9b1285ca",
        "contentType": "VIDEO",
        "title": "Novo Nordisk launches Wegovy pill to US self-pay patients",
        "description": "<title><body><p>STORY: Novo Nordisk is due to launch its once-daily Wegovy weightloss pill in the U.S. from Monday (January 5).</p><p>The Danish drugmaker said it will offer 1.5 and 4 milligram pills at $149 per month to self-paying patients.</p><p>The U.S. Food and Drug Administration approved the pill last month.</p><p>It was a major boost for Novo as it tries to regain lost ground from U.S. rival Eli Lilly.</p><p>It offers a more flexible regime and an alternative for those who don't like needles used in injectable medication.</p><p>The launch could be a positive step for a company which saw profit warnings and sliding shares through last year.</p><p>The semaglutide pills contain the same active ingredient as injectable Wegovy and Ozempic.</p><p>The weight-loss pill version will also be a test case for the fast-growing cash-paying consumer market.</p><p>A key part of making it a success will be attracting cash-paying consumers who can't get insurance coverage.</p><p>That's a big shift from a business model where drug pricing is managed through health insurance plans, which has dominated for decades.</p><p>Novo also said the pill will be sold in 9 mg and a higher long-term dose of 25 mg, which will cost nearly $300 per month.</p></body></title>",
        "summary": "<body><p>STORY: Novo Nordisk is due to launch its once-daily Wegovy weightloss pill in the U.S. from Monday (January 5).</p><p>The Danish drugmaker said it will offer 1.5 and 4 milligram pills at $149 per month to self-paying patients.</p><p>The U.S. Food and Drug Administration approved the pill last month.</p><p>It was a major boost for Novo as it tries to regain lost ground from U.S. rival Eli Lilly.</p><p>It offers a more flexible regime and an alternative for those who don't like needles used in injectable medication.</p><p>The launch could be a positive step for a company which saw profit warnings and sliding shares through last year.</p><p>The semaglutide pills contain the same active ingredient as injectable Wegovy and Ozempic.</p><p>The weight-loss pill version will also be a test case for the fast-growing cash-paying consumer market.</p><p>A key part of making it a success will be attracting cash-paying consumers who can't get insurance coverage.</p><p>That's a big shift from a business model where drug pricing is managed through health insurance plans, which has dominated for decades.</p><p>Novo also said the pill will be sold in 9 mg and a higher long-term dose of 25 mg, which will cost nearly $300 per month.</p></body>",
        "pubDate": "2026-01-05T12:36:16Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/7kud2n44OQsghjsvGLr6NQ--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d4a7e77e-d45c-4462-a54d-56ee57086c2a/main/1280x720/39s137ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M8gntrwIVIGLOkAzSl5jJA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d4a7e77e-d45c-4462-a54d-56ee57086c2a/main/1280x720/39s137ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YH2_lNheVM1qzQ6H4ain1Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d4a7e77e-d45c-4462-a54d-56ee57086c2a/main/1280x720/39s137ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-launches-wegovy-pill-123616915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-launches-wegovy-pill-123616915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T12:07:46+00:00",
    "headline": "Novo Nordisk to Sell Wegovy Pill in U.S. Starting at $149 per Month",
    "summary": "Launch targets self-pay market as company expands weight-loss portfolio",
    "url": "https://finance.yahoo.com/news/novo-nordisk-sell-wegovy-pill-120746635.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "c9929530-3890-32be-9353-ef168808b1ef",
      "content": {
        "id": "c9929530-3890-32be-9353-ef168808b1ef",
        "contentType": "STORY",
        "title": "Novo Nordisk to Sell Wegovy Pill in U.S. Starting at $149 per Month",
        "description": "",
        "summary": "Launch targets self-pay market as company expands weight-loss portfolio",
        "pubDate": "2026-01-05T12:07:46Z",
        "displayTime": "2026-01-05T12:07:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9TzR39bxuUCR99sbuZJDMQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjQrAqlrjUwsW.v1rUBg.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-sell-wegovy-pill-120746635.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-sell-wegovy-pill-120746635.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T04:37:57+00:00",
    "headline": "2 Unpopular Stocks That Deserve Some Love and 1 That Underwhelm",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finance.yahoo.com/news/2-unpopular-stocks-deserve-love-043757295.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "cd3cfe07-6dc7-3857-b046-3b005c716dac",
      "content": {
        "id": "cd3cfe07-6dc7-3857-b046-3b005c716dac",
        "contentType": "STORY",
        "title": "2 Unpopular Stocks That Deserve Some Love and 1 That Underwhelm",
        "description": "",
        "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
        "pubDate": "2026-01-05T04:37:57Z",
        "displayTime": "2026-01-05T04:37:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/19d976841a7cf02344c7d4020c2f5a5c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "ANF Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jv6f8b0C5xrtanropNdkQQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/19d976841a7cf02344c7d4020c2f5a5c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/17S3F0SpkuMnwoYVpYgIWg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/19d976841a7cf02344c7d4020c2f5a5c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-unpopular-stocks-deserve-love-043757295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-unpopular-stocks-deserve-love-043757295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ANF"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "DIN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T14:00:12+00:00",
    "headline": "AI took investors on a date in 2025. In 2026, analysts say it's time to foot the bill.",
    "summary": "As the AI trade becomes \"fractured,\" 2026 could see other stocks finally outshine the \"Magnificent Seven.\"",
    "url": "https://finance.yahoo.com/news/ai-took-investors-on-a-date-in-2025-in-2026-analysts-say-its-time-to-foot-the-bill-140012067.html",
    "source": "Yahoo Finance",
    "provider": "yfinance",
    "raw": {
      "id": "fdc0367e-61f0-4be9-a11f-fc4ab81ee26b",
      "content": {
        "id": "fdc0367e-61f0-4be9-a11f-fc4ab81ee26b",
        "contentType": "STORY",
        "title": "AI took investors on a date in 2025. In 2026, analysts say it's time to foot the bill.",
        "description": "",
        "summary": "As the AI trade becomes \"fractured,\" 2026 could see other stocks finally outshine the \"Magnificent Seven.\"",
        "pubDate": "2026-01-05T14:00:12Z",
        "displayTime": "2026-01-05T14:00:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-01/9e002280-e7f8-11f0-bfef-90c6396630ad",
          "originalWidth": 5027,
          "originalHeight": 3351,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Dq9BdFxaViRaUssaVCGFvg--~B/aD0zMzUxO3c9NTAyNzthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-01/9e002280-e7f8-11f0-bfef-90c6396630ad.cf.webp",
              "width": 5027,
              "height": 3351,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8dW1H1CZcAefrAvuCnzpKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-01/9e002280-e7f8-11f0-bfef-90c6396630ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance",
          "url": "http://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ai-took-investors-on-a-date-in-2025-in-2026-analysts-say-its-time-to-foot-the-bill-140012067.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ai-took-investors-on-a-date-in-2025-in-2026-analysts-say-its-time-to-foot-the-bill-140012067.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MU"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "AVGO"
            },
            {
              "symbol": "OPAI.PVT"
            },
            {
              "symbol": "CVX"
            },
            {
              "symbol": "ORCL"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "WM"
            },
            {
              "symbol": "HD"
            },
            {
              "symbol": "MCD"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "NBIS"
            },
            {
              "symbol": "IREN"
            },
            {
              "symbol": "PANW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T14:20:00+00:00",
    "headline": "Is It Time to Dump Your Shares of Eli Lilly?",
    "summary": "Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.",
    "url": "https://www.fool.com/investing/2026/01/05/is-it-time-to-dump-your-shares-of-eli-lilly/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "3418bfe8-4ae3-3e7b-8982-50f736f0ebd4",
      "content": {
        "id": "3418bfe8-4ae3-3e7b-8982-50f736f0ebd4",
        "contentType": "STORY",
        "title": "Is It Time to Dump Your Shares of Eli Lilly?",
        "description": "",
        "summary": "Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.",
        "pubDate": "2026-01-05T14:20:00Z",
        "displayTime": "2026-01-05T14:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/bf56d0f93471eb40ce4e3a032dcc58f9",
          "originalWidth": 1199,
          "originalHeight": 711,
          "caption": "A person with their hands up in frustration.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kgIoAfuLMeQDW8xDXZXFOQ--~B/aD03MTE7dz0xMTk5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/bf56d0f93471eb40ce4e3a032dcc58f9.cf.webp",
              "width": 1199,
              "height": 711,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/32pt7mXt0obkIRHTkkrLdQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/bf56d0f93471eb40ce4e3a032dcc58f9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/05/is-it-time-to-dump-your-shares-of-eli-lilly/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/time-dump-shares-eli-lilly-142000092.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T14:57:25+00:00",
    "headline": "Novo Nordisk Stock Rises on Launch of Weight-Loss Pills",
    "summary": "Novo Nordisk’s shares rallied after the drugmaker said its new Wegovy weight-loss pill is now broadly available in the U.S., following regulatory approval last month.  The Wegovy product is the first GLP-1 pill approved specifically for weight loss.  It will tap into what analysts expect will be substantial demand from consumers seeking an alternative to the injections that have dominated the anti-obesity market to date.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-05-2026/card/novo-nordisk-stock-rises-on-launch-of-weight-loss-pills-d7qEImU2xtm9BLVcdKhI?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "bfd61aed-0231-3a5c-ba68-1e425e1ccdb8",
      "content": {
        "id": "bfd61aed-0231-3a5c-ba68-1e425e1ccdb8",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Rises on Launch of Weight-Loss Pills",
        "description": "",
        "summary": "Novo Nordisk’s shares rallied after the drugmaker said its new Wegovy weight-loss pill is now broadly available in the U.S., following regulatory approval last month.  The Wegovy product is the first GLP-1 pill approved specifically for weight loss.  It will tap into what analysts expect will be substantial demand from consumers seeking an alternative to the injections that have dominated the anti-obesity market to date.",
        "pubDate": "2026-01-05T14:57:25Z",
        "displayTime": "2026-01-05T14:57:25Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/bfd61aed-0231-3a5c-ba68-1e425e1ccdb8/novo-nordisk-stock-rises-on.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-05-2026/card/novo-nordisk-stock-rises-on-launch-of-weight-loss-pills-d7qEImU2xtm9BLVcdKhI?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "CVS"
            },
            {
              "symbol": "COST"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T13:42:00+00:00",
    "headline": "Novo Nordisk’s Wegovy Pill Now Broadly Available Across U.S.",
    "summary": "Novo Nordisk’s Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisks-wegovy-pill-now-broadly-available-across-u-s-a0db33d7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "af1d95a7-49b6-30fa-8e5e-540698320824",
      "content": {
        "id": "af1d95a7-49b6-30fa-8e5e-540698320824",
        "contentType": "STORY",
        "title": "Novo Nordisk’s Wegovy Pill Now Broadly Available Across U.S.",
        "description": "",
        "summary": "Novo Nordisk’s Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said.",
        "pubDate": "2026-01-05T13:42:00Z",
        "displayTime": "2026-01-05T13:42:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/af1d95a7-49b6-30fa-8e5e-540698320824/novo-nordisk%E2%80%99s-wegovy-pill.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/e83d2d773541faef04f98d3a409db389",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e0BgLnvPpwyh7Pjsw4EP6Q--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/e83d2d773541faef04f98d3a409db389.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jTiPV.FuS9unTJ78fAHifQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/e83d2d773541faef04f98d3a409db389.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisks-wegovy-pill-now-broadly-available-across-u-s-a0db33d7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "CVS"
            },
            {
              "symbol": "COST"
            },
            {
              "symbol": "LFMD"
            },
            {
              "symbol": "WW"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T13:34:00+00:00",
    "headline": "Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?",
    "summary": "Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.",
    "url": "https://finance.yahoo.com/news/nvos-wegovy-pill-approval-obesity-133400049.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2c772f0d-4c81-3a9f-a976-e2518cf99679",
      "content": {
        "id": "2c772f0d-4c81-3a9f-a976-e2518cf99679",
        "contentType": "STORY",
        "title": "Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?",
        "description": "",
        "summary": "Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.",
        "pubDate": "2026-01-05T13:34:00Z",
        "displayTime": "2026-01-05T13:34:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OpV4giEb4QjgN71LPYFzIw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QcLiFahMpkHBfBp4mOYpEQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nvos-wegovy-pill-approval-obesity-133400049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nvos-wegovy-pill-approval-obesity-133400049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T12:41:00+00:00",
    "headline": "Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026",
    "summary": "LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.",
    "url": "https://finance.yahoo.com/news/watch-5-ai-powered-medical-124100059.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "241b4354-6efb-300c-910a-fbe42e13a842",
      "content": {
        "id": "241b4354-6efb-300c-910a-fbe42e13a842",
        "contentType": "STORY",
        "title": "Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026",
        "description": "",
        "summary": "LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.",
        "pubDate": "2026-01-05T12:41:00Z",
        "displayTime": "2026-01-05T12:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/e10425bef32c421f16ccc0d2a8c8bb61",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/q2o6Po.tZIjoCUe46ctOnQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e10425bef32c421f16ccc0d2a8c8bb61.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y_BNpZRIZ5wQucw1oaRq4Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e10425bef32c421f16ccc0d2a8c8bb61.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/watch-5-ai-powered-medical-124100059.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/watch-5-ai-powered-medical-124100059.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ISRG"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]